{'fraction_non_alphanumeric': 0.030789825970548863, 'fraction_numerical': 0.0013386880856760374, 'mean_word_length': 5.8, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Behavioral effects of carbidopa/levodopa in hyperactive boys.

Abstract Eight boys with attention deficit disorder with hyperactivity received a 3-week trial of carbidopa/levodopa (Sinemet(®)) or placebo using a double-blind, crossover design. Carbidopa/levodopa was found to be mildly effective treatment for children, particularly for inattention and classroom restlessness, as rated by the teacher. Levels of norepinephrine metabolites in urine increased with carbidopa/levodopa, but did not correlate with individual clinical improvement within the sample. Although carbidopa/levodopa may be useful in the treatment of individual cases of attention deficit disorder with hyperactivity, the general use of carbidopa/levodopa is not recommended.